-
US to test Paxlovid as long COVID-19 therapy
The National Institutes of Health announced plans to test at least four different treatments for long COVID, including Pfizer’s Paxlovid, as potential therapies for the lasting condition, according to a July 31 news release. -
Biogen to buy rare disease drugmaker for $7.3B
Biogen has agreed to pay $7.3 billion to acquire Reata Pharmaceuticals — the maker of a new treatment for a rare genetic disorder. The deal is expected to close by the end of the year. -
All shortage-vulnerable Pfizer drugs are already in short supply
Of the 13 Pfizer essential drugs the United States Pharmacopeia named as the most likely to go into new or worsened shortages, all of them are already in short supply. -
Experts to CMS: Make Alzheimer's drug data public
More than two dozen physicians, public health researchers and health policy experts are urging the federal government to publicly share registry data on the safety and efficacy of the Alzheimer's drug Leqembi. -
UofL Health opens full-service pharmacy in underserved area
UofL Health's Mary & Elizabeth Hospital in Louisville, Ky., has opened its own full-service pharmacy, according to a July 27 news release. -
Phase 3 trial of postpartum depression med shows good results
A phase 3 trial of an oral drug called zuranolone significantly improved symptoms of postpartum depression in just 15 days. -
Indiana system opens $40M pharmacy hub
Indiana University Health, based in Indianapolis, recently unveiled its $40 million, 70,000-square-foot shared services pharmacy facility, according to a news release shared with Becker's. -
Kaiser Permanente mail-order pharmacy ranks No. 1 in customer satisfaction: JD Power
Kaiser Permanente Pharmacy ranked No. 1 for customer satisfaction among mail-order pharmacies in the J.D. Power 2023 U.S. Pharmacy Study. -
13 essential Pfizer drugs most vulnerable to shortages: USP
Thirteen essential drugs made at Pfizer's Rocky Mount, N.C., facility — which was recently damaged by a tornado — have a vulnerability score higher than 90 percent, according to a July 26 report from United States Pharmacopeia. -
ISMP updates list of look-alike drug names
The Institute for Safe Medical Practices has revised its list of look-alike drug names that are often confused, adding more than 80 drug pairs to the resource. -
4 Mounjaro solutions in shortage
Novo Nordisk is reporting shortages of Ozempic, Wegovy, Saxenda and, recently, Eli Lilly has reported shortages of Mounjaro, a Type 2 diabetes drug that might be approved for weight loss if clinical trials find success. -
WHO excludes weight loss drugs from essential medicines list
The World Health Organization decided to not add GLP-1 receptor agonists indicated for weight loss, such as Wegovy, to its 2023 essential medicines list, which includes about 500 drugs. -
65 drugs at risk of new, worsened shortages after tornado hit Pfizer plant
Pfizer told hospital buyers that 65 of its products "may experience continued or new supply disruptions in the near term" because less than three months' worth of supply is in the market. -
Stomachs freeze up with Ozempic in rare result: 5 updates
Following reports of sunken faces, muscle mass loss and malnutrition with Ozempic, another rare side effect has popped up: severe gastroparesis, or stomach paralysis. -
Biogen to cut 1,000 jobs
Cambridge, Mass.-based Biogen will cut about 1,000 jobs as it plans to save $700 million by 2025, the company said July 25. -
Systems experiment with new drug shortage strategies
As the U.S. drug industry waits to see how a Pfizer plant damaged by a tornado in North Carolina will affect their pharmaceutical supply, hospital pharmacy leaders have been experimenting with new ways to mitigate drug shortages. -
FDA approves 1st drug to treat viral skin disease
The U.S. now has an FDA-approved medication for a viral skin disease that afflicts 6 million people every year. -
Walgreens taps new VP to lead Health Corners strategy
Walgreens has named Monica Reed, PharmD, as vice president of health centers strategy and operations, where she will oversee the company's 'Health Corners' clinics. -
FDA releases strategy for Pfizer's damaged plant
There will not be immediate or significant disruptions to the U.S. hospital drug market after a tornado hit a Pfizer plant in Rocky Mount, N.C., according to the FDA. -
Ohio CVS pharmacy endangered patient, lost 1,800 doses of controlled substances, report finds
Several Ohio CVS pharmacies are under investigation by the state pharmacy board for problems that led to thousands of controlled substances being lost and patient harm after a wrong medication was given, the Ohio Capital Journal reported July 24.
Page 38 of 50